Kao C - Search Results

1

Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model.

Ko SC, Gotoh A, Thalmann GN, Zhau HE, Johnston DA, Zhang WW, Kao C, Chung LW. Ko SC, et al. Among authors: kao c. Hum Gene Ther. 1996 Sep 10;7(14):1683-91. doi: 10.1089/hum.1996.7.14-1683. Hum Gene Ther. 1996. PMID: 8886839

2

Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers.

Gotoh A, Kao C, Ko SC, Hamada K, Liu TJ, Chung LW. Gotoh A, et al. Among authors: kao c. J Urol. 1997 Aug;158(2):636-41. J Urol. 1997. PMID: 9224383

3

Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model.

Cheon J, Ko SC, Gardner TA, Shirakawa T, Gotoh A, Kao C, Chung LW. Cheon J, et al. Among authors: kao c. Cancer Gene Ther. 1997 Nov-Dec;4(6):359-65. Cancer Gene Ther. 1997. PMID: 9408606

4

Human prostate cancer progression models and therapeutic intervention.

Chung LW, Kao C, Sikes RA, Zhau HE. Chung LW, et al. Among authors: kao c. Hinyokika Kiyo. 1997 Nov;43(11):815-20. Hinyokika Kiyo. 1997. PMID: 9436028 Free article. Review.

5

Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.

Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW. Gotoh A, et al. Among authors: kao c. J Urol. 1998 Jul;160(1):220-9. J Urol. 1998. PMID: 9628654

6

Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.

Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HE, Balian G, Chung LW. Wu TT, et al. Among authors: kao c. Int J Cancer. 1998 Sep 11;77(6):887-94. doi: 10.1002/(sici)1097-0215(19980911)77:6<887::aid-ijc15>3.0.co;2-z. Int J Cancer. 1998. PMID: 9714059

7

In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy.

Shirakawa T, Ko SC, Gardner TA, Cheon J, Miyamoto T, Gotoh A, Chung LW, Kao C. Shirakawa T, et al. Among authors: kao c. Cancer Gene Ther. 1998 Sep-Oct;5(5):274-80. Cancer Gene Ther. 1998. PMID: 9824046

8

A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.

Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL, Zhau HE, Kao C, Kamidono S, Gillenwater JY, Chung LW. Matsubara S, et al. Among authors: kao c. Cancer Res. 2001 Aug 15;61(16):6012-9. Cancer Res. 2001. PMID: 11507044

9

Tissue-specific promoters in gene therapy for the treatment of prostate cancer.

Shirakawa T, Gotoh A, Wada Y, Kamidono S, Ko SC, Kao C, Gardner TA, Chung LW. Shirakawa T, et al. Among authors: kao c. Mol Urol. 2000 Summer;4(2):73-82. doi: 10.1089/10915360050138620. Mol Urol. 2000. PMID: 12006246 Review.

10

Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models.

Ko SC, Cheon J, Kao C, Gotoh A, Shirakawa T, Sikes RA, Karsenty G, Chung LW. Ko SC, et al. Among authors: kao c. Cancer Res. 1996 Oct 15;56(20):4614-9. Cancer Res. 1996. PMID: 8840973

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,548 results

Search Page

Filters